The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD
The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr Valve, are a proven, viable, minimally-invasive treatment option for severe emphysema, a form […]
Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer
Financing to Expand the U.S. Launch and Global Commercialization of the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema/COPD REDWOOD CITY, California, May 9, 2019 – Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick […]
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment
New labeling clears the way for the treatment of many more patients.
January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an…
Pulmonx Reports New Publication Confirms Efficacy of Emphysema Treatment
Zephyr® Endobronchial Valve (EBV) therapy guided by Chartis®Assessment is effective in a broad range of patients.
May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the…
Pulmonx to Market Zephyr® EBV Therapy for Patients with “Genetic” Emphysema
Company Receives Approval to Revise CE Labeling
August 29, 2012, Peseux, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that its European notified body has granted CE approval for revised labeling of its Zephyr® Endobronchial Valve (EBV). The approval was…
Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy
IDE for Study of Zephyr® Endobronchial Valve Approved
August 27, 2012, Redwood City, CA, USA – Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to…
FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema
REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for
How the Zephyr® Valve Works
[vc_row][vc_column][vc_video link=”https://vimeo.com/video/205398498″][/vc_column][/vc_row][vc_row][vc_column width=”1/4″][services_medium icon_bool=”image” image=”1618″][/services_medium][/vc_column][vc_column width=”3/4″][vc_column_text]Using a standard bronchoscope, Zephyr Valves are delivered to target airways using a flexible delivery catheter[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/4″][services_medium icon_bool=”image” image=”1619″][/services_medium][/vc_column][vc_column width=”3/4″][vc_column_text]Once implanted, the tiny valve prevents airflow into the diseased region, while allowing trapped air to escape[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/4″][services_medium icon_bool=”image” image=”1620″][/services_medium][/vc_column][vc_column width=”3/4″][vc_column_text]Reducing the volume of the diseased region may allow healthier regions to […]
Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial
SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2018 – Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD)….
Pulmonx Submits Premarket Approval (PMA) Application to U.S. FDA for Zephyr Endobronchial Valve as Treatment for Emphysema
Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment